Skip to content

US · IFRX · BIOTECHNOLOGY

InflaRx N.V. (IFRX) intrinsic value and stock valuation

$1.04as of 2026-11-21 · Mkt cap 132.91M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

InflaRx N.V. DCF and intrinsic value

InvestorsCraft values IFRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IFRX’s statements →

InflaRx N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jena, TH 07745 inflarx.de

How the business is doing

Fiscal 2015–2025, USD

Revenue
$30K
20152025
Net income
-$-45.63M
20152025
Free cash flow
-$-34.03M
20152025
Total equity
$41.5M-11.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$30K$170K$60K$0.00$0.00
Operating income-$-48.26M-$-52.91M-$-44.59M-$-32.24M-$-47.63M
Net income-$-45.63M-$-46.06M-$-42.67M-$-29.48M-$-45.63M
EPSd-$-678.11K-$-781.74K-$-776.67K-$-666.82K-$-1.1M
Operating cash flow-$-33.92M-$-48.56M-$-37.81M-$-33.74M-$-39.94M
Capital expenditure-$-110K-$-50K-$-80K-$-160K-$-40K
Free cash flow-$-34.03M-$-48.6M-$-37.89M-$-33.91M-$-39.97M
Total assets$55.2M$76M$120.2M$102.4M$125.1M
Total debt$900K$810K$1.12M$1.36M$1.43M
Net debt-$-15.12M-$-17.57M-$-11.65M-$-14.91M-$-24.82M
Total equity$41.5M$61.4M$102.6M$88.4M$105.3M
Cash and short-term investments$46.4M$18.4M$12.8M$81.8M$83.4M
Income statement
20252024202320222021
Revenue$30K$170K$60K$0.00$0.00
Cost of revenue$7.27M$3.32M$530K$0.00$0.00
Gross profit-$-7.24M-$-3.15M-$-470K$0.00$0.00
Research and development expenses$25.7M$35.4M$41M$37.5M$35.7M
Selling, general and administrative expenses$17.6M$19.3M$16.1M$14.3M$11.4M
Other expenses-$-2.27M-$-4.94M-$-13.02M-$-19.63M$500K
Operating expenses$41M$49.8M$44.1M$32.2M$47.6M
Cost and expenses$48.3M$53.1M$44.7M$32.2M$47.6M
Interest income$1.77M$3.2M$3.8M$610K$110K
Interest expense$40K$20K$40K$50K$20K
Depreciation and amortization$420K$490K$570K$600K$670K
Ebitda-$-45.16M-$-45.55M-$-42.06M-$-28.84M-$-44.94M
Operating income-$-48.26M-$-52.91M-$-44.59M-$-32.24M-$-47.63M
Total other income/expenses, net$2.64M$6.85M$1.93M$2.75M$2M
Income before tax-$-45.62M-$-46.06M-$-42.67M-$-29.48M-$-45.63M
Income tax expense$10K$10K$0.00$0.00$0.00
Net income-$-45.63M-$-46.06M-$-42.67M-$-29.48M-$-45.63M
Weighted average shares outstanding$67.3M$58.9M$54.9M$44.2M$41.6M
Weighted average diluted shares outstanding$67.3M$58.9M$54.9M$44.2M$41.6M
Balance sheet
20252024202320222021
Cash and short-term investments$46.4M$18.4M$12.8M$81.8M$83.4M
Net receivables$1.43M$0.00$0.00$1.43M$1.28M
Inventory$0.00$6.9M$11.4M$0.00$0.00
Total current assets$53.6M$71.7M$109.5M$97.4M$95.7M
Property, plant and equipment, net$1.15M$1.01M$1.36M$1.64M$1.68M
Goodwill and intangible assets$40K$10K$40K$140K$240K
Long-term investments$240K$3.09M$9.05M$2.9M$27.2M
Total non-current assets$1.58M$4.36M$10.7M$4.99M$29.5M
Total assets$55.2M$76M$120.2M$102.4M$125.1M
Accounts payable$5.4M$3.41M$5.1M$4.99M$1.69M
Short-term debt$260K$410K$370K$370K$370K
Deferred revenue$0.00$0.00$0.00$6.21M$8.3M
Total current liabilities$13M$14.2M$16.8M$13M$18.8M
Long-term debt$640K$400K$750K$990K$1.07M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$680K$440K$780K$1.02M$1.1M
Capital lease obligations$640K$810K$1.12M$1.36M$1.43M
Total liabilities$13.7M$14.6M$17.6M$14.1M$19.9M
Common stock$8.67M$7.12M$7.07M$5.36M$5.3M
Retained earnings-$-377.67M-$-332.19M-$-286.13M-$-243.46M-$-213.98M
Accumulated other comprehensive income (loss)$48.5M$51.6M$47.4M$36.6M$30.6M
Total equity$41.5M$61.4M$102.6M$88.4M$105.3M
Total investments$30.7M$3.09M$9.05M$68.4M$84.4M
Total debt$900K$810K$1.12M$1.36M$1.43M
Net debt-$-15.12M-$-17.57M-$-11.65M-$-14.91M-$-24.82M
Cash flow statement
20252024202320222021
Net income-$-43.83M-$-46.06M-$-42.67M-$-29.48M-$-45.63M
Depreciation and amortization$400K$490K$570K$600K$670K
Stock-based compensation$0.00$4.07M$3.41M$6.04M$4.33M
Change in working capital$4.66M-$-2.28M$1M-$-9.77M$1.54M
Accounts receivable$2.12M$0.00$0.00$0.00$0.00
Inventory$6.63M$4.47M-$-11.37M$0.00$0.00
Accounts payable-$-5.76M$0.00$0.00-$-3.52M$320K
Net cash provided by operating activities-$-33.92M-$-48.56M-$-37.81M-$-33.74M-$-39.94M
Investments in property, plant and equipment-$-110K-$-50K-$-80K-$-160K-$-40K
Acquisitions, net$0.00$0.00$0.00-$-19.52M$40K
Net cash used for investing activities$3.11M$52.4M-$-17.7M$19.4M-$-25.95M
Common stock issued$32.4M$1.1M$56.5M$2.35M$65.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$32M$390K$53M$1.94M$61.6M
Net change in cash-$-180K$5.61M-$-3.5M-$-9.98M$280K
Cash at end of period$16M$18.4M$12.8M$16.3M$26.3M
Operating cash flow-$-33.92M-$-48.56M-$-37.81M-$-33.74M-$-39.94M
Capital expenditure-$-110K-$-50K-$-80K-$-160K-$-40K
Free cash flow-$-34.03M-$-48.6M-$-37.89M-$-33.91M-$-39.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About InflaRx N.V.

        InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

        CEO
        Niels C. Riedemann
        Employees
        65
        Beta
        2.45

        Explore

        Frequently asked questions

        What is the intrinsic value of InflaRx N.V. (IFRX)?

        InvestorsCraft does not currently publish an intrinsic value for IFRX. How the IC value is calculated.

        Is IFRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for IFRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.